DK2646546T3 - Tomm34-peptider og vacciner, der indeholder disse - Google Patents

Tomm34-peptider og vacciner, der indeholder disse Download PDF

Info

Publication number
DK2646546T3
DK2646546T3 DK11846000.5T DK11846000T DK2646546T3 DK 2646546 T3 DK2646546 T3 DK 2646546T3 DK 11846000 T DK11846000 T DK 11846000T DK 2646546 T3 DK2646546 T3 DK 2646546T3
Authority
DK
Denmark
Prior art keywords
peptide
present
peptides
hla
cancer
Prior art date
Application number
DK11846000.5T
Other languages
English (en)
Inventor
Yusuke Nakamura
Takuya Tsunoda
Ryuji Osawa
Sachiko Yoshimura
Tomohisa Watanabe
Gaku Nakayama
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of DK2646546T3 publication Critical patent/DK2646546T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Claims (15)

1. Isoleret peptid, der består af en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 1, 5, 31 og 32, der bibeholder evnen til at binde til et HLA-antigen, hvor HLA-antigenet er HLA-A2.
2. Isoleret peptid, der består af en aminosyresekvens, hvori en eller to aminosyrer er substitueret i en aminosyresekvens valgt fra gruppen, der består af SEQ ID NO: 1, 5, 31 og 32, til opnåelse af et modificeret peptid, der bibeholder evnen til at binde til et HLA-antigen, og til inducering af cytotoksisk T-lymfocyt (CTL), hvor HLA-antigenet er HLA-A2, hvor substitutionen eller substituenterne er valgt fra gruppen, der består af: (a) den anden aminosyre fra N-terminalen er substitueret med methionin, og (b) den C-terminale aminosyre er substitueret med valin eller leucin.
3. Isoleret polynukleotid, der koder for peptidet ifølge krav 1 eller 2.
4. Farmaceutisk sammensætning, der omfatter: (a) et eller flere peptider ifølge krav 1 eller 2; (b) et eller flere polynukleotider ifølge krav 3; (c) en eller flere APC'er, der præsenterer et kompleks af peptidet ifølge krav 1 eller 2 og et HLA-antigen på overfladen; (d) et eller flere exosomer, der præsenterer et kompleks af peptidet ifølge krav 1 eller 2 og et HLA-antigen på overfladen; eller (e) en eller flere CTL'er, der genkender en celle, der præsenterer et kompleks af peptidet ifølge krav 1 eller 2 og et HLA-antigen på overfladen, i kombination med et farmaceutisk acceptabelt bæremiddel, til anvendelse til (i) behandling af en eksisterende cancer, (ii) profylakse af en cancer, (iii) forebyggelse af et postoperativt recidiv af en cancer eller (vi) kombinationer deraf, hvor HLA-antigenet hos individet, der skal behandles, er HLA-A2 .
5. In vitro-fremgangsmåde til inducering af en antigenpræsenterende celle (APC) med evnen til at inducere CTL, som omfatter et trin valgt fra gruppen, der består af: (a) etablering af kontakt mellem en APC og peptidet ifølge krav 1 eller 2 in vitro eller ex vivo og (b) indførelse af et polynukleotid, der koder for peptidet ifølge krav 1 eller 2, i en APC.
6. In vitro-fremgangsmåde til inducering af en CTL, som omfatter et trin valgt fra gruppen, der består af: (a) samdyrkning af en CD8-positiv T-celle med en APC, der på dens overflade præsenterer et kompleks af et HLA-antigen og peptidet ifølge krav 1 eller 2, (b) samdyrkning af en CD8-positiv T-celle med et exosom, der på dets overflade præsenterer et kompleks af et HLA-antigen og peptidet ifølge krav 1 eller 2, og (c) indførelse i en T-celle af et polynukleotid/polynukleotider, der koder for T-cellereceptor (TCR)-subunitpolypeptider, hvor TCR'en, der dannes af TCR-subunitpolypeptiderne, er i stand til at binde til et kompleks af et HLA-antigen og peptidet ifølge krav 1 eller 2 på en celleoverflade, hvor HLA-antigenet er HLA-A2.
7. Isoleret APC, der på dens overflade præsenterer et kompleks af et HLA-antigen og peptidet ifølge krav 1 eller 2.
8. APC ifølge krav 7, der er induceret ved hjælp af en fremgangsmåde til inducering af en antigenpræsenterende celle (APC) med evnen til at inducere CTL, hvor fremgangsmåden omfatter et trin valgt fra gruppen, der består af: (a) etablering af kontakt mellem en APC og peptidet ifølge krav 1 eller 2 in vitro eller ex vivo og (b) indførelse af et polynukleotid, der koder for peptidet ifølge krav 1 eller 2, i en APC.
9. Isoleret CTL, der er rettet mod et hvilket som helst af peptiderne ifølge krav 1 eller 2.
10. CTL ifølge krav 9, der er induceret ved hjælp af en fremgangsmåde til inducering af en CTL, hvor fremgangsmåden omfatter et trin valgt fra gruppen, der består af: (a) samdyrkning af en CD8-positiv T-celle med en APC, der på dens overflade præsenterer et kompleks af et HLA-antigen og peptidet ifølge krav 1 eller 2, (b) samdyrkning af en CD8-positiv T-celle med et exosom, der på dets overflade præsenterer et kompleks af et HLA-antigen og peptidet ifølge krav 1 eller 2, og (c) indførelse i en T-celle af et polynukleotid/polynukleotider, der koder for T-cellereceptor (TCR)-subunitpolypeptider, hvor TCR'en, der dannes af TCR-subunitpolypeptiderne, er i stand til at binde til et kompleks af et HLA-antigen og peptidet ifølge krav 1 eller 2 på en celleoverflade, hvor HLA-antigenet er HLA-A2.
11. Vektor, der omfatter en nukleotidsekvens, der koder for peptidet ifølge krav 1 eller 2.
12. Værtscelle, der er transformeret eller transficeret med en ekspressionsvektor ifølge krav 11.
13. Exosom, der præsenterer et kompleks, der omfatter peptidet ifølge krav 1 eller 2 og et HLA-antigen, hvor HLA-antigenet er HLA-A2.
14. Antistof mod peptidet ifølge krav 1 eller 2.
15. Diagnostisk kit, der omfatter peptidet ifølge krav 1 eller 2, polynukleotid ifølge krav 3 eller antistof ifølge krav 14.
DK11846000.5T 2010-12-02 2011-11-25 Tomm34-peptider og vacciner, der indeholder disse DK2646546T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41918110P 2010-12-02 2010-12-02
PCT/JP2011/006551 WO2012073459A1 (en) 2010-12-02 2011-11-25 Tomm34 peptides and vaccines including the same

Publications (1)

Publication Number Publication Date
DK2646546T3 true DK2646546T3 (da) 2018-08-06

Family

ID=46171433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11846000.5T DK2646546T3 (da) 2010-12-02 2011-11-25 Tomm34-peptider og vacciner, der indeholder disse

Country Status (23)

Country Link
US (3) US9125849B2 (da)
EP (1) EP2646546B1 (da)
JP (2) JP6064186B2 (da)
KR (1) KR102004900B1 (da)
CN (2) CN105111281A (da)
AR (1) AR084095A1 (da)
AU (1) AU2011336019B2 (da)
BR (1) BR112013013158B1 (da)
CA (1) CA2819463C (da)
CO (1) CO6862100A2 (da)
DK (1) DK2646546T3 (da)
EA (1) EA028216B1 (da)
ES (1) ES2677118T3 (da)
IL (1) IL226068B (da)
MX (1) MX344586B (da)
MY (1) MY166516A (da)
NZ (1) NZ611361A (da)
PH (1) PH12013501105A1 (da)
SG (2) SG190407A1 (da)
TW (1) TWI618541B (da)
UA (1) UA110119C2 (da)
WO (1) WO2012073459A1 (da)
ZA (1) ZA201303886B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2895600B1 (en) 2012-09-11 2020-02-19 OncoTherapy Science, Inc. Ube2t peptides and vaccines containing the same
JP2015228191A (ja) * 2014-06-03 2015-12-17 カシオ計算機株式会社 コンテンツ出力システム、コンテンツ出力方法、コンテンツ出力プログラム、および通信端末
WO2017150084A1 (ja) * 2016-02-29 2017-09-08 京セラドキュメントソリューションズ株式会社 電子機器およびマーカー処理方法
SI3573600T1 (sl) 2017-01-25 2022-07-29 Ose Immunotherapeutics Postopek za proizvodnjo obstojne emulzije za dostavo peptida

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5539084A (en) 1989-02-17 1996-07-23 Coselco Mimotopes Pty. Ltd. Method for the use and synthesis of peptides
NZ263550A (en) * 1993-03-19 1996-12-20 Boehringer Ingelheim Int Preparing cancer vaccines containing autologous tumour cells characterised in that tumour cells or firbroblasts are cultivated and transfected ex vivo with a composition of dna and a dna binding molecule conjugate
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US20020137683A1 (en) 2000-01-03 2002-09-26 Hogan Kevin T. C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040181344A1 (en) 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
DE60336227D1 (de) 2002-06-06 2011-04-14 Oncotherapy Science Inc Gene und proteine mit bezug zu menschlichem kolonkrebs
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
EP2261247A3 (en) * 2002-09-12 2011-02-16 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
EP1581812B1 (en) 2003-01-06 2008-07-16 Wyeth Compositions and methods for diagnosing and treating colon cancers
JP5156882B2 (ja) * 2003-04-18 2013-03-06 アイディーエム ファーマ，インコーポレイティド Ｈｌａ−ａ２腫瘍関連抗原ペプチドおよび組成物
RU2526196C2 (ru) * 2005-07-27 2014-08-20 Онкотерапи Сайенс, Инк. Связанный с раком толстого кишечника ген том34
PT1760089E (pt) * 2005-09-05 2009-10-19 Immatics Biotechnologies Gmbh Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena
TWI610939B (zh) 2007-02-21 2018-01-11 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
HUE030856T2 (en) * 2009-03-18 2017-06-28 Oncotherapy Science Inc Neil3 peptides and vaccines including the same

Also Published As

Publication number Publication date
CA2819463C (en) 2018-10-23
EP2646546A1 (en) 2013-10-09
EA028216B1 (ru) 2017-10-31
CN103339253A (zh) 2013-10-02
EP2646546B1 (en) 2018-05-16
AU2011336019A1 (en) 2013-07-04
SG10201509823WA (en) 2015-12-30
WO2012073459A1 (en) 2012-06-07
TWI618541B (zh) 2018-03-21
AU2011336019B2 (en) 2016-07-07
EP2646546A4 (en) 2015-12-23
BR112013013158B1 (pt) 2020-04-28
US20140023671A1 (en) 2014-01-23
SG190407A1 (en) 2013-06-28
ES2677118T3 (es) 2018-07-30
AR084095A1 (es) 2013-04-17
UA110119C2 (xx) 2015-11-25
CN103339253B (zh) 2015-09-09
NZ611361A (en) 2014-10-31
US20150374810A1 (en) 2015-12-31
TW201225973A (en) 2012-07-01
BR112013013158A2 (pt) 2017-08-01
MX344586B (es) 2016-12-20
CA2819463A1 (en) 2012-06-07
US9125849B2 (en) 2015-09-08
US9585948B2 (en) 2017-03-07
KR102004900B1 (ko) 2019-07-29
JP2016222676A (ja) 2016-12-28
KR20130121910A (ko) 2013-11-06
IL226068B (en) 2019-01-31
CN105111281A (zh) 2015-12-02
US20170198010A1 (en) 2017-07-13
ZA201303886B (en) 2014-03-26
MX2013006014A (es) 2013-07-29
EA201390811A1 (ru) 2013-12-30
JP2014506114A (ja) 2014-03-13
PH12013501105A1 (en) 2013-08-05
JP6064186B2 (ja) 2017-01-25
IL226068A0 (en) 2013-06-27
CO6862100A2 (es) 2014-02-10
MY166516A (en) 2018-07-05

Similar Documents

Publication Publication Date Title
DK2408913T3 (da) Neil3-peptider og vacciner, der indeholder disse
DK2771350T3 (da) Topk-peptider og vacciner, der indbefatter disse
WO2012169200A1 (en) Sema5b peptides and vaccines including the same
WO2011125334A1 (en) Cdca5 peptides and vaccines including the same
US20170198010A1 (en) Tomm34 peptides and vaccines including the same
WO2010131452A1 (en) Ttk peptides and vaccines including the same
WO2010100878A1 (en) Vangl1 peptides and vaccines including the same
DK2553096T3 (da) Ect2-peptider og vacciner, der indbefatter disse
WO2012032764A1 (en) Ttll4 peptides and vaccines containing the same
WO2011074236A1 (en) Tmem22 peptides and vaccines including the same
WO2011111392A1 (en) Hjurp peptides and vaccines including the same
WO2011067933A1 (en) Mybl2 peptides and vaccines containing the same
WO2014087626A1 (en) Sema5b peptides and vaccines containing the same
WO2012053200A1 (en) C18orf54 peptides and vaccines including the same
WO2012053206A1 (en) Wdhd1 peptides and vaccines including the same
WO2011125139A1 (en) Cluap1 peptides and vaccines including the same
WO2012032763A1 (en) Vangl1 peptides and vaccines including the same
HK1189391A (en) Tomm34 peptides and vaccines including the same
HK1189391B (en) Tomm34 peptides and vaccines including the same
HK1180003A (en) Ect2 peptides and vaccines including the same
HK1180003B (en) Ect2 peptides and vaccines including the same